Lakeshore I (LAAA) Secures $30M for ProSomnus Deal
by Marlena Haddad on 2022-08-26 at 5:18pm

Lakeshore Acquisition I Corp. (NASDAQ:LAAA) has signed definitive agreements for $30 million in convertible notes for its combination with medical device company ProSomnus.

The recent commitment of debt financing comes from institutional investors led by funds affiliated with or managed by Cohanzick Management, LLC and CrossingBridge Advisors, LLC, but the closing of the notes are conditioned upon the closing of the business combination prior to December 10, 2022.

The $30 million debt facility, which is being issued to various institutional parties, is comprised of two tranches:  $15 million of senior secured convertible notes and $15 million of junior secured convertible notes with maturities of 36 months and 40 months, respectively.

Following the issuance, within 12 months, the debt will be eligible for secondary trading. The senior debt has an initial conversion price of $13.00, which is to be reset at 5% premium to market price six and twelve months after closing, subject to a floor while the subordinated debt has an initial conversion price of $11.50, to be reset to a 5% premium to the market price six and twelve months after close and subject to a floor.

The financing plays an important role in closing Lakeshore’s business combination with ProSomnus. With Lakeshore bringing in $55 million into the deal from its current trust, the $30 million in convertible notes will help strengthen the company’s balance sheet. The parties disclosed the term sheet for the senior and junior notes at deal announcement, but at that time the funding was not definite as it was subject to today’s signing of the definitive convertible debt agreements. Lakeshore must maintain at least $40 million in cash and cash equivalents available after closing.

Lakeshore and ProSomnus disclosed that they expect to use the proceeds of the facility to fund multiple strategic growth initiatives such as continued growth of the sales team to expand the company’s international presence. ProSomnus also plans to complete the development of its next-generation Oral Appliance Therapy, which features sensors that allow physicians to monitor their patients during critical hours.  Other initiatives for ProSomnus include investments in manufacturing techniques, raising efforts of public awareness of Obstructive Sleep Apnea, and the value-added features of the company’s new therapy devices.

The combined company is expected to change its name to ProSomnus, Inc. and its class A common stock is expected to be traded on the Nasdaq Capital Market under the symbol “OSA”.

The parties initially announced the $168 million combination a few months ago on May 10. Pleasanton, California-based ProSomnus customizes oral appliance therapy devices to treat obstructive sleep apnea. Precision oral appliance therapy is a new option for treating obstructive sleep apnea, where each ProSomnus device is personalized and digitally manufactured to match the anatomy and treatment plan for each patient.

 

 

Lakeshore I (LAAA) Secures $30M for ProSomnus Deal
Recent Posts
by Nicholas Alan Clayton on 2025-07-08 at 8:11pm

Globa Terra Acquisition Corporation (NASDAQ:GTERU) announced the pricing of its $152 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “GTERU”, Wednesday, July 9, 2025. The new SPAC plans to mount a search for a target in the agriculture, agtech or biotech sectors with an emphasis on water...

by Nicholas Alan Clayton on 2025-07-08 at 12:36pm

M3-Brigade V (NASDAQ:MBAV) has entered into a definitive agreement to combine with crypto treasury firm ReserveOne, assembling about $1 billion in equity funding. ReserveOne is setting up a diversified Bitcoin and digital asset treasury with a portion of its investments going towards blockchain infrastructure and venture raises. The combined company is expected to trade on...

by Nicholas Alan Clayton on 2025-07-08 at 8:18am

At the SPAC of Dawn As the SPAC market has warmed in 2025, only 21 of the 70 SPACs (30%) that have IPO’d thus far have overfunded their trusts to draw in investors and none of these funded to more than 101%. By contrast, 87% of 2023 SPACs were overfunded – some to as high...

by Nicholas Alan Clayton on 2025-07-07 at 9:05am

Emmis Acquisition Corporation (NASDAQ:EMISU) has filed for a $100 million SPAC to take a look at the manufacturing sector after a few unique wrinkles in their IPO process. Initial investors are set to receive one right to a 1/10 share in each unit purchased and the SPAC will have 18 months to complete a business...

by Nicholas Alan Clayton on 2025-07-07 at 8:50am

Chenghe III (NASDAQ:CHEC.U) has filed for a $110 million SPAC to continue the team’s growing series while turning to a new underwriter. The new SPAC is offering investors a 1/2 warrant in each unit and no overfunding of the trust, but it will need to complete a business combination within 18 months of its IPO...

logo

Copyright © 2025 SPACInsider, Inc. All Rights Reserved